Abstract
Infections caused by endemic viruses, and the vaccines used to control them, often provide cross-protection against related viruses. This cross-protection has the potential to alter the transmission dynamics and likelihood of emergence of novel zoonotic viruses with pandemic potential. Here, we investigate how changes in population immunity after the COVID-19 pandemic have impacted the likelihood of emergence of a novel sarbecovirus, termed SARS-CoV-X. We show that sera from patients with different COVID-19 immunological histories possess cross-neutralising antibodies against the spike (S) protein of multiple zoonotic sarbecoviruses. Mathematical simulations using these viruses show a significant reduction in their likelihood of emergence in populations with current levels of SARS-CoV-2 natural and vaccine-derived immunity, with the outcome determined by the extent of cross-protection and the R_0 of the novel virus. We also show that preventative vaccination programs against SARS-CoV-X using currently available COVID-19 vaccines can help resist emergence even in the presence of co-circulating SARS-CoV-2. However, it was possible for a theoretical vaccine with very high specificity to SARS-CoV-2 (i.e., one which elicits very low cross-protection against SARS-CoV-X) to increase the likelihood of SARS-CoV-X emergence, due to its effects on SARS-CoV-2 prevalence and, by extension, the levels of naturally-derived cross-protection in the human population. Overall, our findings show that SARS-CoV-2 circulation and COVID-19 vaccination have generated widespread population immunity against antigenically related sarbecoviruses, and this new immunological barrier is likely to be a strong determinant of the ability of novel sarbecoviruses to emerge in humans.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the following sources: Medical Research Council MC_UU_0034/3 (PRM), MC_UU_00034/6 (BJW) & MR/Y002814/1 Biotechnology and Biological Sciences Research Council BB/V004697/1 (PRM, MV)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of National Health Service Greater Glasgow and Clyde (NHSGGC) Biorepository gave ethical approval for this work (application 550).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos